Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2005

Filing Date
Filed February 7, 2006
Period End
December 31, 2005
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 7, 2006. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported a net loss of $22.2 milliona, or $0.60 per share, for 2005, compared with a net loss of $45.8 million, or $1.26 per share, in 2004.

Total revenues rose to $123.9 millionb from $85.2 million, driven mainly by $70.0 million in milestones from Pfizer tied to FDA acceptance of the indiplon NDAs, along with a $22.0 million sales force allowance from Pfizer. Research and development expenses fell to $106.6 million from $115.1 million as the indiplon Phase III program wound down, while sales, general and administrative expenses rose to $42.3 million, reflecting the 200-person sales force. The company had an accumulated deficit of $300.1 million and cash, cash equivalents and short-term investments of $273.1 million at December 31, 2005.

The central near-term catalyst is indiplon for insomnia. The FDA accepted NDAs for the capsule and tablet formulations, and the PDUFA dates were moved to May 15, 2006 for the capsule and June 27, 2006 for the tablet, with the FDA committing to an action on both by May 15, 2006. The company says it expects 2006 to be roughly break-even before indiplon royalty revenue and the adoption of SFAS 123R, but profitability depends on FDA approval and market acceptance.

Pfizer, the collaboration partner, may terminate its agreement on 180 days' notice. The pipeline includes GnRH antagonists for endometriosis and benign prostatic hyperplasia, altered peptide ligands for multiple sclerosis and type 1 diabetes, CRF receptor antagonists with GlaxoSmithKline, and urocortin 2 for heart failure. The company states that its existing capital resources and collaboration payments will be sufficient for at least the next 12 months.

Key Highlights

  1. 2005 net loss narrowed to $22.2 million ($0.60 per share) from $45.8 million ($1.26 per share) in 2004.
  2. Total revenues were $123.9 million, up from $85.2 million, mainly due to $70.0 million in Pfizer milestones tied to FDA acceptance of the indiplon NDAs.
  3. Pfizer agreed to fund a 200-person Neurocrine sales force, recognizing a $22.0 million sales force allowance in 2005.
  4. Indiplon NDAs for capsule and tablet forms have PDUFA dates of May 15, 2006 (capsule) and June 27, 2006 (tablet), with the FDA committing to act on both by May 15, 2006.
  5. Cash, cash equivalents and short-term investments were $273.1 million at December 31, 2005, down from $301.1 million.
  6. Accumulated deficit reached $300.1 million; the company says 2006 is expected to be roughly break-even before indiplon royalties and SFAS 123R expense.
  7. Pipeline includes GnRH antagonists for endometriosis and BPH, altered peptide ligands for multiple sclerosis and type 1 diabetes, CRF antagonists partnered with GlaxoSmithKline, and urocortin 2 for congestive heart failure.

Frequently Asked Questions

  1. What is the key near-term catalyst for Neurocrine Biosciences?

    The FDA's decision on the indiplon NDAs for insomnia. The FDA committed to act on both the capsule and tablet NDAs by May 15, 2006, with PDUFA dates of May 15, 2006 and June 27, 2006, respectively. Profitability in 2006 depends on approval and on prescriber and consumer acceptance.

  2. How is the company funding indiplon's commercialization?

    Pfizer is responsible for substantially all third-party development, manufacturing and commercialization costs and funds a 200-person Neurocrine sales force that promotes Zoloft and will co-promote indiplon in the United States. Pfizer may terminate the collaboration on 180 days' written notice.

  3. Why did revenue increase in 2005?

    Revenue rose to $123.9 million from $85.2 million, primarily because of $70.0 million in milestones from Pfizer related to the FDA accepting the indiplon NDAs for review, along with a $22.0 million sales force allowance.

  4. Does the company have enough cash to fund operations?

    The company believes its existing capital resources, interest income and future strategic alliance payments will be sufficient for at least the next 12 months. It held $273.1 million in cash, cash equivalents and short-term investments at December 31, 2005, but says those resources might be insufficient to conduct all programs as planned.

  5. What accounting change will affect future results?

    Beginning in 2006, the company will adopt SFAS 123R and expense employee stock options. To reduce this expense, it accelerated vesting of approximately 472,000 unvested options in November 2005, which eliminated about $10.5 million of expense that would otherwise have been recognized over the remaining vesting period.